Physician profile
Renee Sons
NPI 1548783400
$1,028.69
in general payments reported to CMS, 2019-2025
13 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $155 · 2023: $314 · 2024: $230 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $468.75 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $120.35 | 2023-2025 | |
| Novo Nordisk INC | $108.60 | 2022-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $102.15 | 2022-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $68.54 | 2022-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $31.97 | 2024 | Rexulti |
| Astellas Pharma US INC | $25.09 | 2025 | Veozah |
| Phadia US INC. | $20.22 | 2024 | Immunocap |
| Exact Sciences Corporation | $19.47 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $18.74 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $16.67 | 2023 | Trulicity, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $14.10 | 2022 | |
| Glaxosmithkline, LLC. | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Sons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.